We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
After hours:
Chart Events
Performance Outlook
| Previous Close | 4.2200 |
| Open | 4.2500 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 4.1209 - 4.3689 |
| 52 Week Range | 2.5000 - 18.0000 |
| Volume | |
| Avg. Volume | 54,783 |
| Market Cap | 6.798M |
| Beta (5Y Monthly) | 1.32 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -23.3100 |
| Earnings Date | May 08, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for AVGR
Related Research
- Avinger, Inc.Analyst Report: Medtronic PLCWith operational headquarters in Minnesota, Medtronic is one of the world's largest medical technology and solutions companies. Its devices focus on cardiac rhythm management, spinal and surgical navigation technologies, treatments for diabetes and neurological conditions, vascular therapies, and cardiac surgery. MDT is a component of the S&P 500.RatingFair ValueEconomic MoatyesterdayArgus Research
ZacksAvinger (AVGR) Upgraded to Buy: What Does It Mean for the Stock?
Avinger (AVGR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ZacksAre Medical Stocks Lagging Edwards Lifesciences (EW) This Year?
Here is how Edwards Lifesciences (EW) and Avinger (AVGR) have performed compared to their sector so far this year.
Insider MonkeyAvinger, Inc. (NASDAQ:AVGR) Q4 2023 Earnings Call Transcript
Avinger, Inc. (NASDAQ:AVGR) Q4 2023 Earnings Call Transcript March 20, 2024 Avinger, Inc. misses on earnings expectations. Reported EPS is $-3.93 EPS, expectations were $0.64. AVGR isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings. Welcome to Avinger’s Fourth Quarter […]
ACCESSWIREAvinger Reports Fourth Quarter and Full Year 2023 Results
New Strategic Partnership Provides Funding to Support U.S. Growth Initiatives and Coronary Product Development, Opens New Pathway for Sales in Asia REDWOOD CITY, CA / ACCESSWIRE / March 20, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical ...
- ACCESSWIRE
Avinger to Announce Full Year 2023 Results on March 20, 2024
REDWOOD CITY, CA / ACCESSWIRE / March 12, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, ...
- ACCESSWIRE
Avinger Announces Strategic Partnership and up to $15 Million Equity Funding Agreement with Zylox-Tonbridge
Initial $7.5 Million Strategic Investment Strategic Partnership Opens Pathway to Access Greater China Market Strengthened Balance Sheet and Three-Year Extension of Existing Debt Terms REDWOOD CITY, CA / ACCESSWIRE / March 6, 2024 / Avinger, Inc. (Nasdaq:AVGR), ...
Insider MonkeyAvinger, Inc. (NASDAQ:AVGR) Q3 2023 Earnings Call Transcript
Avinger, Inc. (NASDAQ:AVGR) Q3 2023 Earnings Call Transcript October 26, 2023 Avinger, Inc. misses on earnings expectations. Reported EPS is $-2.92 EPS, expectations were $-2.85. Operator: Greetings. Welcome to the Avinger Third Quarter 2023 Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. […]
ZacksAvinger (AVGR) Reports Q3 Loss, Lags Revenue Estimates
Avinger (AVGR) delivered earnings and revenue surprises of -2.46% and 24.29%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
- ACCESSWIRE
Avinger Reports Third Quarter 2023 Results
REDWOOD CITY, CA / ACCESSWIRE / October 26, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of ...
- ACCESSWIRE
Avinger to Announce Third Quarter 2023 Results on October 26
REDWOOD CITY, CA / ACCESSWIRE / October 19, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, ...
People Also Watch
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| JAGX Jaguar Health, Inc. | |||
| BIOL BIOLASE, Inc. | |||
| ACST Acasti Pharma Inc. | |||
| CHEK Check-Cap Ltd. | |||
| GHSI Guardion Health Sciences, Inc. |
Similar to AVGR
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| FEMY Femasys Inc. | |||
| GCTK GlucoTrack, Inc. | |||
| BNGO Bionano Genomics, Inc. | |||
| STXS Stereotaxis, Inc. | |||
| LUCY Innovative Eyewear, Inc. |
Analyst Price Targets (1)
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/21/2024 | |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/8/2024 | |
| Maintains | HC Wainwright & Co.: Buy to Buy | 11/13/2023 |
Company Profile
400 Chesapeake Drive
Redwood City, CA 94063
United States
650 241 7900
https://avinger.com
Sector(s): Healthcare
Industry: Medical Instruments & Supplies
Full Time Employees: 68
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, including Ocelot and Tigereye, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is headquartered in Redwood City, California.
